The Association Between Serum Riboflavin and Flavin Mononucleotide With Pancreatic Cancer

Abstract

Objectives Vitamin B2 (riboflavin) has a prime role in metabolic reactions imperative to cell cycle and proliferation. We investigated the associations between serum concentrations of riboflavin flavin mononucleotide with the risk of pancreatic cancer in a nested case-control study involving 58 cases and 104 matched controls. Methods The Singapore Chinese Health Study, an ongoing prospective cohort study of 63,257 Chinese Singaporeans. Conditional logistic regression method was used to evaluate these associations with adjustment for potential confounders including the level of education, body mass index, smoking status, alcohol consumption, history of diabetes, serum cotinine and pyridoxal 5′-phosphate, estimated glomerular filtration rate, and total methyl donors (ie, the sum of serum choline, betaine, and methionine). Results The risk of pancreatic cancer increased with increasing level of serum riboflavin in a dose-dependent manner, especially in men (P trend = 0.003). The odds ratio (95% confidence intervals) of pancreatic cancer for the second and third tertiles of serum riboflavin, compared with the lowest tertile, were 9.92 (1.65–59.77) and 25.59 (3.09–212.00), respectively. This positive association was stronger in individuals with a longer follow-up period (≥7 years). Conclusions The findings suggest a potential role of riboflavin in the development of pancreatic cancer, especially in men.